Objectives: In patients with pancreatic ductal adenocarcinoma (PDAC), increased expression of proinflammatory neurotrophic growth factors (eg, nerve growth factor [NGF]) correlates with a poorer prognosis, perineural invasion, and, with regard to NGF, pain severity. We hypothesized that NGF sequestration would reduce inflammation and disease in the KPC mouse model of PDAC.
The increased production/concentration of neurotrophic factors by tumor cells and intrapancreatic nerve fibers raises the question as to whether suppression of growth factor signaling might inhibit the development and progression of pancreatic disease. Nerve growth factor is a prime candidate for this role because of its strong neurotropic effects on peripheral neurons (reviewed by Mendell et al 26 and Jankowski and Koerber
27
). Nerve growth factor not only promotes neuronal survival but is also a key modulator of neurogenic inflammation (NI) and pain through its upregulation of inflammatory peptides (eg, calcitonin gene-related peptide [CGRP] and substance P [SP] ) and its sensitizing effects on sensory neuron firing properties. Several completed and ongoing clinical trials have used NGF sequestration as a strategy to block pain signaling. [28] [29] [30] [31] [32] [33] [34] Preclinically, NGF sequestration has ameliorated pain behaviors in a variety of animal models, with the most relevant being pancreatitis postsurgical pain and metastatic cancer pain. [35] [36] [37] Although the role of NGF in cancer pain has been documented, there is limited information available regarding how NGF signaling impacts cancer progression. Studies of human and murine PDAC cell lines indicate that NGF can promote proliferation, migration, and invasiveness of tumor cells. 20, [38] [39] [40] Other in vitro and xenograft experiments show that NGF antibody (anti-NGF) treatment or siRNA-mediated knockdown of NGF reduces cell proliferation and inhibits growth of breast, prostate, and oral squamous carcinomas. 25, 41, 42 However, there are no studies that directly examine how suppression of NGF signaling affects PDAC in an in vivo transgenic model.
Genetically engineered mouse models (GEMMs) of PDAC that express the most common human mutation associated with the disease (Kras G12D ) provide an important physiologically relevant tool to investigate the role of growth factor signaling. These GEMMs share many of the pathological features of human PDAC including temporal progression of precursor lesions (pancreatic intraepithelial neoplasias [PanINs] ) to primary and metastatic tumors. With disease progression, intrapancreatic nerve fibers exhibit hypertrophy, and mice exhibit pain-related behaviors that correlate with a significant up-regulation of NGF and its receptor TrkA. 43 Interestingly, during initial acinar-to-ductal metaplasia and early PanIN development, the peripheral nervous system exhibits signs of injury that may be linked to an influx of pancreatic lineage cells and up-regulation of neural inflammatory markers. 44 These data are in line with other studies reporting that dissemination of pancreas-lineage cells precedes tumor formation. 45, 46 Because increased NGF/TrkA expression is correlated with greater inflammation, cell proliferation, invasion, and poorer prognosis in both humans and xenograft models, we explored the hypothesis that NGF sequestration could reduce neural inflammation and impede PDAC development in a physiologically relevant GEMM.
MATERIALS AND METHODS

Animals
The KPC mouse model of PDAC was used for all experiments. 44 In this model, the Pft1a/p48 promoter drives expression of a mutant Kras allele (LSL-Kras G12D ), and 1 allele of the p53 tumor suppressor gene is deleted in a Cre-dependent manner. Some KPC mice also expressed the fluorescent reporter protein tdTomato in a Cre-dependent manner. Mice were group housed in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited Division of Laboratory Animal Resources at the University of Pittsburgh. They were maintained in a 12-hour light-dark cycle and temperature-controlled environment with ad libitum access to water and food. Mice were cared for and used in these studies following guidelines of the Institutional Animal Care and Use Committee at the University of Pittsburgh and the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Anti-NGF Treatment
Mice were randomly assigned to receive biweekly intraperitoneal injections of anti-NGF (200 μg/kg, catalog AF-556-NA; R&D Systems, Minneapolis, Minn) or immunoglobulin G (IgG, 200 μg/kg; R&D Systems) beginning at either age 4 or 8 weeks. Unless mice succumbed to disease prematurely (n = 3), animals were euthanized via an overdose of inhaled isoflurane, perfused transcardially with saline at 16 weeks of age or greater and tissue collected for analyses.
Antibody Immunolabeling
Mice were killed with inhaled isoflurane and perfused with saline. Superior cervical ganglia (SCG) and dorsal root ganglia (DRG) were removed, postfixed for 30 minutes in 4% paraformaldehyde and cryoprotected in 25% (wt/vol) sucrose in 0.1 M phosphate buffer at 4°C. Pancreata were postfixed overnight in 4% paraformaldehyde with 15% (vol/vol) picric acid prior to cryoprotection. Superior cervical ganglia and pancreata were embedded in Tissue-Tek OCT compound (Sakura Finetek USA, Torrance, Calif), sectioned at 14 and 30 μm, respectively, and mounted on Superfrost Plus slides (Fisher Scientific, Pittsburgh, Pa). Sections were incubated in 10 mM citrate buffer, pH 6.0, for 3 to 8 minutes at 95°C followed by 20 minutes at room temperature, then washed, blocked with 5% (vol/vol) normal horse serum in 0.1 M phosphate buffer containing 0.25% Triton X-100, and incubated overnight in primary antibody. Antibodies used were as follows: anti-tyrosine hydroxylase (anti-TH) (1:500, AB152; Millipore, Temecula, Calif) or anti-CGRP (1:500, C8198; Sigma-Aldrich, St Louis, Mo). Floating thoracic spinal cord sections (30 μm) were incubated overnight in anti-glial fibrillary acidic protein (GFAP) (1:500, 3670S clone GA5; Cell Signaling Technology, Danvers, Mass) or anti-NeuN (1:500, MAB377 clone A60; Millipore). Following incubation with primary antibody, sections were washed, and immunoreactivity was detected using dyeconjugated secondary antibodies (1:500; Jackson ImmunoResearch Laboratories, West Grove, Pa). Sections were photographed using LAS software version 4.7 (Leica Microsystems, Buffalo Grove, Ill) and a Leica DM 4000B microscope and fluorescent intensity measured using Image J version 1.49 (National Institutes of Health, Bethesda, Md).
Western Immunoblot Analysis
Total protein was extracted on ice by homogenization in 50 mM Tris·HCl lysis buffer (pH 7.4) containing 0.5% sodium dodecyl sulfate and protease inhibitors (Cell Signaling Technology). Protein concentration was determined via bicinchoninic acid assay (Fisher Scientific), and aliquots (40 μg) separated on 12% sodium dodecyl sulfate-polyacrylamide gels by electrophoresis. Gels were transferred to polyvinylidene difluoride membranes using the Transblot system (Bio-Rad, Hercules, Calif ). Nonspecific binding was blocked using 5% (wt/vol) bovine serum albumin, membranes were incubated overnight in primary antibodies directed against phosphorylated ERK (p-ERK) (p44/42) or GFAP (1:1000; Cell Signaling Technology), and protein bands were detected using horseradish peroxidase-conjugated secondary antibodies (1:5000). Membranes were washed and then probed with glyceraldehyde-3-phosphate dehydrongenase (GAPDH) or total ERK antibodies as loading controls. Densitometry readings were performed using SuperSignal Chemilumescent Detection reagents (Fisher Scientific), an LAS3000 imager (Fujifilm, Stamford, Conn), and Image J software. Protein levels were normalized to the IgG-treated groups.
Semiquantitative Real-Time Polymerase Chain Reaction
RNA from thoracic-level DRG (T9-T12) was isolated using the RNeasy mini kit (Qiagen, Germantown, Md), treated with DNase (Invitrogen, Pittsburgh, Pa) and reverse transcribed using Superscript II reverse transcriptase (Invitrogen). SYBR green polymerase chain reaction (PCR) amplification was performed using a BioRad CFX connect real-time system. After amplification, a dissociation curve was plotted against melting temperature to ensure amplification of a single product. All samples were run in duplicate and control reactions run (eg, reverse transcription and PCR carried out without template). The relative fluorescence of SYBR green bound to double-stranded DNA was compared with a passive reference for each cycle. Threshold cycle (C t ) values were used as a measure of initial template concentration. Fold changes in RNA levels were calculated by the ΔΔC t method using GAPDH as a reference standard: C t values from duplicate samples were averaged and then subtracted from the reference standard, yielding ΔC t . Primer sequences are available upon request.
Histopathologic Analysis
Animals were examined for the presence of gross metastatic tumors at the time of dissection. The pancreas was then dissected en bloc with stomach and spleen, and the number of additional organs involved was noted (observed range, 0-3). Hematoxylin-eosin-stained sections of deidentified pancreas were used to define the disease stage for each animal (independently by Drs A.D.S. and D.J.H.). Histopathology of lesions and fibroinflammatory stroma was quantified by measuring the percentage of total analyzed surface area occupied. For each case, 10 to 15 fields of view were analyzed. Lesions were classified as low-grade (PanIN-1/2), high-grade (PanIN-3), or PDAC (tumor) based on the 2015 classification guidelines. 47 
Statistical Analysis
All numerical data were compared using 2-way analysis of variance (ANOVA) followed by Sidak test for multiple comparisons. Categorical data (disease stage) were compared using a cumulative link model. Ordinal data (number of metastatic sites) were analyzed using Poisson regression.
RESULTS
Anti-NGF Reduces Markers Associated With NI and PDAC Progression
In the absence of intervention, PDAC progression and behavioral hypersensitivity in the KPC GEMM are associated with increased expression of growth factors, growth factor receptors, and neuropeptides associated with NI. 43, 44 To determine if suppression of NGF signaling alters these PDAC-induced changes, we used reverse transcriptase-polymerase chain reaction, protein immunoblotting, and tissue immunolabeling to assess relative expression in anti-NGF-and IgG-treated KPC mice. We first examined mRNAs encoding the NGF receptors, TrkA and p75. 26, 48 Both were significantly decreased in DRG of anti-NGF-treated mice compared with IgG-treated ice, which was expected if sequestration of NGF ligand by antibody injection was effective. Specifically, there was a main effect of anti-NGF on TrKA mRNA regardless of age at onset of intervention (drug: F 1,30 = 78.65, P < 0.0001; Fig. 1A ). Anti-NGF also reduced p75 mRNA, with a greater reduction in the group that began treatment at 8 weeks of age (time Â treatment: F 1,30 = 18.94, P = 0.0001; Fig. 1B ). The decrease in NGF receptors was accompanied by a reduction in mRNAs that encode proinflammatory peptides. For example, Tac1 (tachykinin 1), which encodes SP, was decreased in DRG from KPC mice that began treatment at 8 weeks of age as compared with IgG-treated mice (time: F 1,26 = 18.90, P = 0.0002; Fig. 1C ). Compared with IgG-treated mice, CalcB mRNA, which encodes CGRP, was decreased in mice that started anti-NGF at 4 weeks of age but was down-regulated to a greater extent in mice that started treatment at 8 weeks (time Â treatment: F 1,34 = 13.48, P = 0.0008; Fig. 1D ). Anti-NGF treatment did not affect mRNA encoding transient receptor potential cation channel subfamily V member 1 (a channel shown to be important for inflammatory pain 49 ) (Fig. 1E) , but a significant increase in DRG mRNA encoding the related transient receptor potential cation channel subfamily A member 1 (TRPA1) channel was seen in mice beginning anti-NGF treatment at 4 weeks of age was measured (time Â treatment: F 1,30 = 4.536, P = 0.041; Fig. 1F ).
Perineural invasion in PDAC is associated with local nerve injury and neuritis that is accompanied by increased spinal glial activation in both human and mouse. 5, 44 To determine if anti-NGF impacts PDAC-associated glial activation, levels of GFAP were assessed in the thoracic spinal cord, at the vertebral levels that innervate the pancreas. 50 Staining of thoracic spinal cord sections suggested a reduction in GFAP immunoreactivity and a lack of "activated morphology" (as signified by the punctate nature of the staining) in the 8-week treatment group (Fig. 2A) . The effects of anti-NGF of GFAP expression were quantified by immunoblotting of total protein from spinal cord, which showed a reduction of GFAP level in anti-NGF mice compared with IgG-injected mice that was dependent on the age at treatment onset (time Â treatment: F 1,36 = 9.71, P = 0.004). KPC mice that began treatment at 4 weeks exhibited no effect of anti-NGF on GFAP level, whereas mice treated at 8 weeks of age exhibited significantly lower GFAP immunoreactivity compared with all other groups (Fig. 2B) .
Anti-NGF injections were also found to have an effect on spinal levels of p-ERK, an indicator of inflammation and pain 51 that is elevated at the PanIN stage of PDAC development. 5, 44 Spinal p-ERK was increased in mice that began anti-NGF injections at 4 weeks of age compared with all other groups, whereas there was no difference observed in the 8-week anti-NGF group compared with either IgG-treated group (time Â treatment interaction: F 1,36 = 8.51, P = 0.006; Fig. 2C ). The differential increase in TRPA1 mRNA and p-ERK protein suggests that timing of anti-NGF intervention is a significant factor: at 4 weeks, when animals are relatively healthy, anti-NGF may drive neural inflammation, whereas intervention at 8 weeks, when PanINs are present, inhibits neural inflammation.
Anti-NGF Does Not Directly Impact Primary Disease
To determine the effects of anti-NGF treatment on the initial occurrence of PDAC, sections of pancreatic tissue were scored in a blinded manner to classify animals based on the most severe lesion present: normal, low-grade PanIN, high-grade PanIN, or FIGURE 1. Anti-NGF treatment alters levels of mRNAs encoding genes related to nociception and NI in DRG T9-T12. A, TrkA and (B) p75 mRNA levels are significantly reduced following anti-NGF treatment regardless of age at onset of intervention. C, Substance P (Tac1) mRNA is significantly decreased in ganglia from mice treated with anti-NGF beginning at 8 weeks of age. D, Calcitonin gene-related peptide (CalcB) is significantly down-regulated by anti-NGF. E, TRPV1 (transient receptor potential cation channel subfamily V member 1) mRNA levels are unchanged by anti-NGF treatment. F, TRPA1 mRNA is significantly increased in thoracic DRG in the 4-week anti-NGF group. Fold-change data were compared by 2-way ANOVA followed by Sidak post hoc test. *P < 0.05, ***P < 0.001, ****P < 0.0001, n = 6-10/group. and this variability prevented the detection of significant differences in any of the measured parameters (Figs. 3C-F) . However, it is worth noting that 25% of the 8-week anti-NGF exhibited no pancreatic disease, whereas all mice in the other groups exhibited abnormal pancreata, suggesting that suppression of NGF signaling may slow the development of pancreatic disease.
Anti-NGF Therapy Reduces Tumor Cell Mobility and Metastases
To assess the effect of anti-NGF on PNI, we crossed a Credependent tdTomato allele into the KPC GEMM. TdTomato expression enabled tracking of pancreas-lineage cells that disseminated from the pancreas to the thoracic spinal cord (Figs. 4A,  B) . Pancreatic cell invasion of the thoracic spinal cord was present in 100% of mice that began treatment (anti-NGF or IgG) at 4 weeks of age, whereas there was a significant reduction in the proportion of mice exhibiting PNI in the 8-week anti-NGF group (logistic regression, P = 0.045; Fig. 4C ). In order to assess the extent of PNI, the average number of tdTomato expressing cells in a 0.25-mm 2 region of interest (indicated in Fig. 4B ) was determined in 5 random sections of spinal cord per mouse. There was a significant reduction in the extent of PNI in the 8-week anti-NGF group relative to the 4 weeks and IgG treatment groups (time Â treatment: F 1,18 = 16.57, P = 0.0007; Fig. 4D ).
In vitro and xenograft studies suggest growth factor signaling stimulates the invasive and migratory capabilities of cancer cells. 20, [38] [39] [40] A prediction from these observations is that suppression of growth factor signaling in a GEMM should reduce metastases. We found that similar to other studies 52, 53 grossly detectable metastases were present in 30.2% (13/43) of untreated KPC mice. Importantly, anti-NGF treatment affected this critical disease feature in a manner dependent on the age at treatment onset. In the 4-week group, the same number of mice exhibited metastasis regardless of treatment (Fig. 5) . However, mice that began anti-NGF treatment at 8 weeks of age exhibited a complete absence of grossly detectable metastatic tumors (Poisson regression, P = 0.007). That later intervention reduces metastases suggests that anti-NGF treatment could be used as a potential neoadjuvant to restrict tumor cells to the pancreas, providing a greater chance for successful surgical intervention.
DISCUSSION
Inflammation and tissue injury are key features of PDAC that extend beyond the pancreas to the nervous system. Perineural invasion and increased levels of neurotrophic factors correlate with poorer prognosis. [22] [23] [24] [25] In mice, neural inflammation and PNI occur early in the disease process and are accompanied by an upregulation of NGF. 43, 44 In the current study, we present evidence that suppressing the rise in NGF can inhibit neural inflammation and restrict the dissemination of pancreas cells. If the extent of dissemination predicts the incidence of recurrence following pancreatic resection, the ability to inhibit cell migration from the diseased pancreas could significantly enhance the potential for successful treatment.
Our data show the effects of anti-NGF therapy depend on the time at which treatment begins. Intervention initiated at 4 weeks (when mice are healthy) had no influence on PNI or spinal GFAP expression when assayed at 16 weeks of age. However, the percentage of mice with involvement of multiple (>1) additional organs was higher if anti-NGF treatment was begun at 4 weeks, suggesting that sequestration of NGF prior to the appearance of disease may worsen the outcome. Mechanistically, this may relate to an increase in NI, as suggested by the increased levels of TRPA1 and p-ERK in this group. This change in inflammation could be due to the long-term suppression of NGF signaling (ie, starting at 4 weeks), which may generate an imbalance in growth factor signaling that promotes the development and aggressiveness of the disease. 21, 54, 55 Nerve growth factor sequestration may also impact other cell types in the tumor microenvironment. Nerve growth factor is essential for the survival and differentiation of sympathetic neurons, 56 and anti-NGF treatment significantly reduced transcription of TH in the postganglionic sympathetic neurons of the SCG (F 1,25 = 23.81; P < 0.001; Supplementary Fig. 1 , http://links.lww.com/MPA/A656). Interestingly, both p75 and TrkA are also expressed by immune cells. 57 Reduction of NGF could therefore impact neural-immune communication and in so doing impede immune surveillance of tumor progression. 12, 20, 21, 54, 55, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] Significant differences in the cellular microenvironment on which anti-NGF is acting (healthy at 4 weeks vs pathological at 8 weeks) could also contribute to the time-dependent effects we observed.
In contrast to mice that began treatment at 4 weeks, mice treated with anti-NGF beginning at 8 weeks, when PanINs are typically present, exhibited significant differences in disease parameters. In 8-week mice, we observed a significant decrease in SP and CGRP in primary afferents, as well as a reduction in GFAP, a marker of spinal astrocyte activation and inflammation. Second, anti-NGF starting at 8 weeks correlated with a significant reduction in the migration of tdTomato-expressing cells to the spinal cord. The ability of pancreas-derived cells to migrate from the pancreas is proposed to reflect cells undergoing an epithelial-tomesenchymal transition, during which invasive and stem-like properties are acquired. 68, 69 Early epithelial-to-mesenchymal transition and dissemination of pancreas-derived cells (preceding tumor formation) have previously been documented in PDAC GEMMs. 44, 45 Anti-NGF-mediated inhibition of pancreatic cell invasion of the cord therefore suggests a reduction in metastatic potential, spinal inflammation, and cancer-related pain. Finally, animals treated with anti-NGF starting at 8 weeks exhibited a significant decrease in gross metastasis, with none of the treated mice exhibiting tumors outside the pancreas. In humans, the absence of pancreatic cell dissemination, and ultimately metastasis, is the difference between a prognosis in which resection can produce long-term survival versus one in which surgery is unlikely to prevent recurrence.
Whether the primary effect of anti-NGF treatment is on sensory afferents, sympathetic efferents, or both, remains to be determined. Early sensory denervation is sufficient to slow or block tumorigenesis in an animal model of PDAC, 44, 70 but sympathetic denervation was sufficient to reduce tumor burden in a model of prostate cancer. [71] [72] [73] [74] If sympathetic neurons have a prominent role in PDAC progression, a prediction is that anti-NGF would have a more robust effect than that seen in prior studies where only sensory neurons were depleted using neonatal capsaicin treatment. 44, 70 Our results show this does not occur, at least in the treatment paradigm used (starting treatment at either 4 or 8 weeks). Although not killing sensory or sympathetic neurons, 33 anti-NGF did decrease TH immunoreactivity in the SCG, as well as reduced mRNAs encoding TrKA and p75, in DRG, which confirms anti-NGF bioactivity. Even so, this treatment was not sufficient for total denervation of the pancreas because TH immunoreactivity and CGRP immunoreactivity were still present in nerve fibers within the pancreata of treated animals ( Supplementary Fig. 2 , http:// links.lww.com/MPA/A656).
That ablation (surgical or chemical) of adult sensory and/or sympathetic innervation of the pancreas is a useful strategy is suggested by studies demonstrating the efficacy of celiac plexus block or ganglion neurolysis for palliative pain management in PDAC patients with unresectable PDAC. [75] [76] [77] [78] In one of the first double-blind, placebo-controlled study, patients with unresectable PDAC received either placebo or 50% ethanol-induced celiac plexus block. 79, 80 Patients who received an ethanol-induced splanchnicectomy survived significantly longer than did salinetreated patients (median, 9.15 vs 6.75 months). An initial interpretation of this study was that patients lived longer because sensory depletion and resulting reduction in pain led to an improved quality of life. Unfortunately, subsequent studies failed to detect similar effects on survival, although all concluded that celiac block/ neurolysis significantly improved quality of life. 76, 78 In the context of the present study, results indicate that the time at which an antineural intervention is carried out is critical. Thus, neuron ablation or anti-NGF treatment must be performed within a window where inhibition of aberrant tumor-nerve interactions is effective. The challenge is to identify when this window of opportunity appears in each individual human patient.
